$AMWL

Zamansky Dmitry sold $110K of AMWL

Zamansky Dmitry (Chief Product & Tech. Officer) sold 8,442 shares of American Well Corp (AMWL) at $13.00 ($0.11M total) on 2026-10-01.

Original reporting
SEC EDGAR · Zamansky Dmitry
Published Oct 5, 2026, 9:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AMWL
Bearish
medium confidence
Mentioned
$AMWL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMWLBearishLow
01

Why it matters

The disclosure provides transparency but the modest size limits market impact.

02

Market read

A small insider sale that may cause slight short‑term pressure on AMWL shares.

03

What to watch

The officer's holdings remain sizable, and the sale was executed via an open‑market transaction without a 10b5‑1 plan.

Relevance 4/10Novelty 4/10Timing: post-filing today

Background

SEC Form 4 filing discloses insider transactions required by regulators.

Company-level read

Ticker impact

$AMWLBearishMedium confidence
Context

Chief Product & Tech Officer sold 8,442 shares for $109,746, reducing his stake to 224,178 shares.

Expected impact

likely slight downward pressure as investors price the insider sell

Evidence & confidence

Insider sales, especially by a senior officer, are often interpreted as a negative signal, though the amount is modest.

Market effects

Minimal impact on the broader telehealth sector; the sale is company‑specific.

No discernible regional effect.

Limited to investors tracking AMWL.

Counterpoint

The sale may be routine portfolio rebalancing and not indicative of future performance.

Key entities

  • American Well Corp

    Provider of telehealth services, ticker AMWL.

  • Zamansky Dmitry

    Chief Product & Tech Officer at AMWL.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMWLMedAI 8/10

American Well (AMWL) Q2 2026 Earnings Call Transcript

American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.

$AMWLMed

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026 BOSTON, August 4 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30, 2026

$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).